During the development of a clinical trial protocol, when should overdose and special situation be included in the safety reporting section?
Are the overdose and special situation reporting requirements applicable only to marketed products which is a investigational medicinal product, or are they also required for investigational medicinal products never get marketing authority?
For unmarketed investigational medicinal products, is it acceptable not to include the reporting requirements for them in the protocol?